tbuckley/cabot-search huggingface dataset:
The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride
Authors: A A Kurland, O L McCabe, T E Hanlon, D Sullivan
Journal: American Journal of Psychiatry (1977)

The authors treated 12 schizophrenic patients who had overt hallucinatory symptoms with intravenously administered naloxone hydrochloride, a narcotic antagonist purported to have antihallucinatory properties. They found no evidence of the effectiveness of naloxone in preventing hallucinations over that of placebo when administered in a randomized, double-blind fashion.
Sampling Methods
Authors: DIETER Y. KOLLER
Journal: American Journal of Respiratory and Critical Care Medicine (2000)

Asthma and other recurrent wheezing disorders, cystic fibrosis, acute respiratory distress syndrome, and chronic lung disease of prematurity are the most frequent pediatric disorders in which inflammatory processes within the airways play a crucial role (1-3). Although airway inflammation is of crucial pathogenetic importance in these diseases, because direct access to the airways is rarely possible, alternative markers of airway inflammation are needed for diagnostic and therapeutic purposes (Table 1). This article explores the use of biomarkers in peripheral blood and in urine (4, 5) as possible indirect measures to study airway inflammation (Table 2). In particular, the article focuses on the use of biomarkers, especially the use of eosinophil granule proteins in the blood and urine of children with asthma/wheezy bronchitis and cystic fibrosis, in comparison with healthy subjects.
Abstract 1285: A functional liaison between E2F and aberrant ETS oncogenes
Authors: Sven Bilke, Raphaela Schwentner, Yang Fan, Max Kauer, Robert L. Walker, Heinrich Kovar, Paul S. Melyzer
Journal: Cancer Research (2012)

Abstract Timing, mode and amplitude of gene regulation depend on the tissue specific dynamic composition of transcription factor complexes. Abnormalities of the constituents of the complex are expected to modify the regulatory behavior of the entire module. Here we report a novel E2F-ETS proliferation control module in Ewing's sarcoma. FLI1 and other ETS factors are frequently found to be fused to EWS in this highly aggressive pediatric cancer of the bone. In a genome-wide localization analysis of EWS/FLI1 as well as E2F3 by ChipSeq, two patterns associated with distinct gene sets and modes of regulation were identified and integrated with gene expression data. EWS/FLI1 significantly colocalized with E2F3 to proximal promoters of activated proliferation genes while EWS/FLI1 binding independent of E2F3 occurred predominantly distant to repressed differentiation genes. We find that this key module of the transcription factor network underlying Ewing's sarcoma is of general importance and not limited to this specific ETS driven neoplasm. Recently, prostate cancer was shown to frequently harbor fusions of the ERG gene. Here we demonstrate that the ETS/E2F3 complex is also present in VCap prostate cancer cells, identify a common set of genes responsive to this module and computationally show that this set of core-responders is involved in proliferation control and translation. Acknowledgement: This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1285. doi:1538-7445.AM2012-1285
Fistulization of self-expanding metal stent from right colon into duodenum
Authors: N. Samadder, J. Fang, D. Adler, B. Sklow
Journal: Endoscopy (2012)

Colonic obstruction has been reported in 7 % – 29 % of patients with colorectal cancer. Endoscopic placement of a self-expandable metal stent (SEMS) to relieve obstruction is often used for palliation or as a "bridge" to elective surgery [1]. We describe a unique complication of colonic SEMS placement.
Sturge-Weber Syndrome With Transient Focal Hyperperfusion
Authors: Kaname Matsumura, Yoshio Watanabe, Shigeru Aoki, Katsuyuki Machii, Tadanori Hirano, Kan Takeda, Hiromichi Nakashima, Tsuyoshi Nakagawa, Shigeki Kuzuhara
Journal: Clinical Nuclear Medicine (1996)

The authors present a case of a 72-year-old woman with Sturge-Weber syndrome showing transient postictal hyperperfusion on I-123 IMP SPECT. Brain SPECT obtained 2 days after the seizure demonstrated hyperperfusion in the affected cortex shown by CT and MRI. The follow-up SPECT obtained 26 days later showed hypoperfusion in the corresponding area. This case shows that patients with the Sturge-Weber syndrome may have hyperperfusion in the pathologic cerebral regions in the postictal phase.
Some Preoperative Warnings of Potential Operating-Room Deaths
Authors: James E. Eckenhoff
Journal: New England Journal of Medicine (1956)

CAREFUL study of the circumstances surrounding the deaths of surgical patients has proved profitable in defining groups of patients who are candidates for catastrophe in the operating room or in the immediate postoperative period. Many of the hazards involved are generally recognized and understood. Others may be apparent if the anesthetist, surgeon or internist studies the problem before operation. In a final group the mechanism of the complication is obscure, and forewarning comes only from previous experience. It is the purpose of this report to attempt to classify these hazards and to relate certain experiences encountered by the anesthesia service . . .
Abstract 33: Microarray analysis of zeranol induced gene expression in primary cultured human breast cancer epithelial cells
Authors: Weiping Ye, Pingping Xu, Saiyi Zhong, Shu-Hong Lin, Jie-Yu Liu, Young C. Lin
Journal: Cancer Research (2011)

Abstract Zeranol (Z) is a nonsteroidal mycotoxin with potent estrogenic activity. Z is one of six growth promoters approved by the FDA for use in the U.S. beef industry to accelerate weight gain, improve feed efficiency and increase the lean meat-to-fat ratio. Recently, the safety meat products from Z-implanted beef has been questioned on the basis that increased exposure of bioactive Z residues may have adverse health implications. Our previous study showed that serum, meat and meat extracts derived from beef cattle implanted with Z significantly stimulated the proliferation of primary cultured human normal and cancerous breast epithelial cells, primary cultured human breast pre-adipocytes, and human breast cancer cell lines. However, little is known about the mechanisms of Z stimulation on the growth of different types of breast cells. To systematically investigate gene expression patterns in primary cultured human breast cancer epithelial cells (PCHBCECs) after Z treatment, we performed DNA microarray analysis. After PCHBCECs were isolated from breast cancer tissue, they were treated with 30 nM Z or 0.1% DMSO, as a vehicle control, for 48 hr, and then mRNA was isolated and purified for gene expression analysis using the Human Genome U133 Plus 2.0 Array TM (Affymetrix Co. Ltd) in the Microarray Shared Resources at The Ohio State University Comprehensive Cancer Center. DNA microarray data were generated on the basis of the criteria of signal intensity and signal ratio. Our results showed that 10 genes were down-regulated and 25 genes were up-regulated in PCHBCECs treated with 30 nM Z as compared to the controls. Among the genes regulated by Z were, limb-bud and heart (LBH) and annexin-1 (ANXA1) which were decreased 2.27 and 2 fold, respectively and human HMG-CoA synthase 1 (HMGCS1) and methyltransferase like 7A (METTL7A) which were up-regulated to 3.8 and 3.25 fold, respectively compared with the controls. Our preliminary data also showed that Z decreased the expression of several tumor suppressor genes, such as protein tyrosine phosphatase γ (PTPγ), p16, p21, and increased DNMT1 expression in PCHBCECs which suggests epigenetic modification of Z in their promoter regions. Our results indicate that long term consumption of beef products with low level of Z or its metabolites might have adverse health effects on human breast. Further validation of our DNA microarray results is in progress in our laboratory (Supported by NIH R01Grant ES 015212). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 33. doi:10.1158/1538-7445.AM2011-33
CDC Moves on Chronic Diseases
Authors: J. Burklow
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article CDC Moves on Chronic Diseases Get access John Burklow John Burklow Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 23, 6 December 1989, Pages 1776–1777, https://doi.org/10.1093/jnci/81.23.1776 Published: 06 December 1989
Abstract LB-295: Targeted therapy of human osteosarcoma cell lines
Authors: Yan Yu, Nuha Ibrahim, William R. Walsh, Jia Lin Yang
Journal: Cancer Research (2012)

Abstract A &amp;lt;20% survival rate for metastatic and recurrent osteosarcoma reflects the inadequacy of available therapies. We aimed to [1] investigate the therapeutic effect of a multikinase inhibitor (sorafenib, gift from Bayer) alone or as a radiosensitizor in human osteosarcoma cell lines, [2] establish a 143B orthotopic mouse model of human osteosarcoma with lung metastasis to identify ras down stream signaling pathways, and [3] assess effect of blocking specific pathway on 143B invasion using a MEK/ERK inhibitor (U0126). Osteosarcoma cell lines, 143B (HOS cell line with k-ras oncogene transformation), HOS and U-2 OS were used in an in vitro experiments. The 143B was also used to set up an orthotopic osteosarcoma mouse model. Clonogenic assay was used to assess the anti-cell growth and anti-colony formation effects of sorafenib and/or radiotherapy (Therapax 3 System) respectively. Immunohistochemistry was used to measure ras down stream signaling factors from both local tumor and lung secondaries of the mouse model. A Matrigel assay was used to assess 143B invasion under interference. IC50s for sorafenib (µg/ml) and x-ray (Gy) were 14.98 and 2.72 (143B), 6.52 and 1.48 (HOS) and 7.72 and 1.49 (U-2 OS) respectively. Ras transformed 143B was relatively insensitive to sorafenib monotherapy. Sorafenib can enhance x-ray treatment in HOS (5-26%) and U-2 OS (4-26%), but not in 143B. The 143B was then used to be injected into the left tibia of 15 nude mice and showed tumor mass at both local area and lung. Detection of ras down stream signaling factors, we found that total MEK, Akt, p38 and phosphorylated MEK (p-MEK), but not p-Akt and p-p38 were positive in both local tumors and lung secondaries. Leiomyosarcoma controls expressed p-Akt and p-MEK, but not p-p38. The 143B cells treated with U0126 had significantly lower in vitro invasion ability compared with controls. Our results indicated that sorafenib may enhance radiotherapy in vitro in some of the osteosarcoma cell lines without overexpression of k-ras gene. The Ras/Raf/MEK/ERK, may play an important role in osteosarcoma lung metastasis, and the targeting MEK/ERK by its specific inhibitor may have a potential use in the effective treatment of osteosarcoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-295. doi:1538-7445.AM2012-LB-295
The novel t(11;12;18)(q21;q13;q21) represents a variant translocation of the t(11;18)(q21;q21) associated with MALT-type lymphoma
Authors: J Dierlamm, EM Murga Penas, M Daibata, H Tagushi, K Hinz, M Baens, J Cools, G Schilling, L Michaux, P Marynen, I Miyoshi, DK Hossfeld
Journal: Leukemia (2002)
Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia
Authors: Seth E. Karol, Leonard A. Mattano, Wenjian Yang, Kelly W. Maloney, Colton Smith, ChengCheng Liu, Laura B. Ramsey, Christian A. Fernandez, Tamara Y. Chang, Geoffrey Neale, Cheng Cheng, Elaine Mardis, Robert Fulton, Paul Scheet, F. Anthony San Lucas, Eric C. Larsen, Mignon L. Loh, Elizabeth A. Raetz, Stephen P. Hunger, Meenakshi Devidas, Mary V. Relling
Journal: Blood (2015)
Induction of Abortion with Mifepristone (RU 486) and Oral or Vaginal Misoprostol
Authors: Hazem El-Refaey, Dhamnasekar Rajasekar, Mona Abdalla, Lynda Calder, Allan Templeton
Journal: New England Journal of Medicine (1995)

Medical termination of pregnancy can be successfully performed with a combination of mifepristone (RU 486) and a prostaglandin analogue. We conducted a prospective, randomized trial to compare oral with vaginal administration of the prostaglandin E1 analogue misoprostol for first-trimester abortion in women treated initially with mifepristone.
Asymmetric FDG Uptake in a Lactating Breast
Authors: MERRICK SHOR, NEENA DAVE, MADHUSUDHAN REDDY, AMJAD ALI
Journal: Clinical Nuclear Medicine (2002)

SHOR, MERRICK M.D.; DAVE, NEENA M.D.; REDDY, MADHUSUDHAN M.D.; ALI, AMJAD M.D. Author Information
COMPARISON OF APPROACHES FOR “NET CLINICAL BENEFIT” IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: A NETWORK META-ANALYSES OF RANDOMIZED CONTROL TRIALS
Authors: Navkaranbir S. Bajaj, Rajat Kalra, Garima Arora, Taimoor Hashim, Ty Whitfield, Hemant Godara, Sameer Ather, Steven Lloyd, Pankaj Arora
Journal: Journal of the American College of Cardiology (2016)
A memorable teacher: Care with case notes
Authors: H. Saxton
Journal: BMJ (2002)

In October 1954 I was the newly appointed registrar to Dr John Bolton, physician and geriatrician, waiting to begin my first ward round. I had, I thought, got the details of all the cases ready, but I was still nervous. Dr Bolton had not been at the interview when I was appointed, but the ward sister and the houseman assured me that he was a nice person.

We began at the first patient and discussed her. I felt happy with what I had suggested. As we ended, I started to move towards the next bed. Dr Bolton, however, asked sister for the patient's notes and carefully …
Regulation of Somatic-Cell Therapy and Gene Therapy by the Food and Drug Administration
Authors: David A. Kessler, Jay P. Siegel, Philip D. Noguchi, Kathryn C. Zoon, Karyn L. Feiden, Janet Woodcock
Journal: New England Journal of Medicine (1993)

Scientific advances in the past decade have made the clinical testing of somatic-cell therapy and gene therapy a reality. Early trials in humans suggest that important new diagnostic and therapeutic tools are on the horizon. The objectives of this article are to examine the regulation of somatic-cell and gene therapy by the Food and Drug Administration (FDA) in the context of the agency's traditional role in the development of biologic products and to stimulate discussion in areas in which policy is still being formulated. The technology of somatic-cell and gene therapy has moved from the bench to clinical evaluation with . . .
S93 COPD and risk of lung cancer: The importance of smoking and timing of diagnosis of COPD: Abstract S93 Table 1
Authors: HA Powell, B Iyen-Omofoman, DR Baldwin, RB Hubbard, LJ Tata
Journal: Thorax (2012)

<h3>Background</h3> The majority of cases of both lung cancer and COPD are attributable to cigarette smoking. Some consider COPD to be an independent risk factor for lung cancer, even after accounting for smoking, with estimates of increased risk up to 9-fold in previous studies. We undertook a large case-control study using prospectively collected data which allowed us to quantify this association in the UK population, whilst carefully controlling for smoking and the impact of timing of diagnoses. <h3>Methods</h3> We used The Health Improvement Network, a UK general practise database, to identify incident cases of lung cancer and controls matched on age, sex and the practise with which they were registered. Using conditional logistic regression, we assessed the effects of timing of first diagnoses of COPD, pneumonia and asthma on the odds of lung cancer, adjusting for smoking habit and socioeconomic status. <h3>Results</h3> Of 11,888 incident cases of lung cancer, 23% had a prior diagnosis of COPD compared with only 6% of the 37,605 controls. The odds of lung cancer in patients who had COPD diagnosed within 6 months of their cancer diagnosis were eleven-fold those of patients without COPD. However, when restricted to earlier COPD diagnoses, with adjustment for smoking, the effect markedly diminished (for COPD diagnoses &gt;10 years before lung cancer diagnosis OR 2.18, 95% CI 1.87–2.54). The pattern was similar for pneumonia (see table). There was some diagnostic overlap between asthma and COPD but analyses which accounted for this produced similar results. <h3>Conclusion</h3> The association between COPD and lung cancer is largely explained by smoking habit, strongly dependent on the timing of COPD diagnosis and not specific to COPD. There is, however, an extremely strong unadjusted relationship of both COPD and pneumonia with lung cancer in the 6 months immediately prior to lung cancer diagnosis. This is useful in a clinical context highlighting the need to consider a diagnosis of lung cancer when making new diagnoses of COPD or pneumonia, and supporting the current NICE recommendation that all patients should have a chest radiograph looking for evidence of lung cancer at the time of COPD diagnosis.
AT-12 * PHASE 1/2 STUDY OF TH-302, INVESTIGATIONAL HYPOXIA-ACTIVATED PRODRUG, AND BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA
Authors: A. Brenner, J. Floyd, C. Eng, S. Kroll, L. Fichtel, A. Gruslova, A. Lodi, S. Tiziani
Journal: Neuro-Oncology (2014)

BACKGROUND: Hypoxia is implicated in the pathogenesis of glioblastoma multiforme (GBM), and greater hypoxic burden is associated with poorer outcomes in GBM. Treatment with bevacizumab (BEV) may increase intratumoral hypoxia. An ongoing phase 1/2 study (NCT01403610) investigates safety and activity of TH-302, an investigational hypoxia-activated prodrug, combined with BEV in patients with BEV-refractory GBM. METHODS: Single center, dose-escalation, prospective study with 2:1 randomization to TH-302 single dose of 575 mg/m2 or placebo administered pre-surgery (cohorts 1-3 only), followed by post-surgery combination therapy of BEV at 10 mg/kg and TH-302 dose escalated 240-670 mg/m2 every 2 weeks (4-week cycle) until disease progression. Following the first 5 patients in cohort 3, patients were allowed to proceed directly to TH-302/BEV combination therapy without surgery. RESULTS: Twenty three patients have been enrolled: 14 randomized in presurgery cohorts 1-3 with 9 proceeding to TH-302/BEV after surgery and 9 additional patients proceeding directly to TH-302/BEV. No grade 4 adverse events (AEs) were observed. Three grade 3 AEs in 3 patients were observed: skin ulceration at 340 mg/m2, thrombocytopenia at 670 mg/m2, and oral mucositis at 670 mg/m2. Primary TH-302-related toxicities were mucosal, but not dose limiting: rectal mucositis in 1/4 patients at 480 mg/m2 and 6/8 patients at 670 mg/m2 (all grade 1 or 2). Oral mucositis was limited. Best tumor responses in 18 evaluable patients: 1 complete response, 3 partial responses, and 9 stable disease. Median progression-free survival (PFS) was 3.1 mos (95% CI: 2.0 to 4.0 mos) and 4-month PFS was 26% (95% CI: 4% to 47%). CONCLUSIONS: The recommended phase 2 dose of TH-302 is 670 mg/m2 when combined with BEV. These preliminary data suggest potential activity of TH-302/BEV in GBM patients with poor prognosis. Dose expansion at 670 mg/m2 of TH-302 is ongoing.
AB0243 Relationship between bone mineral density and radiographic damage in established rheumatoid arthritis patients under biologics
Authors: M. Bernardes, T. Vieira, G. Terroso, J. Abelha-Aleixo, P. Madureira, R. Vieira, R. Fonseca, D. Gonçalves, A. Bernardo, S. Pimenta, A. Oliveira, T. Faria, C. Gonçalves, J. G. Pereira, M. J. Martins, J. C. Machado, L. Costa, F. Simões-Ventura
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is characterized by a periarticular demineralization, namely in the hands, as well as a generalized osteoporosis. Both processes and joint damage are related to an imbalance in osteoclast and osteoblast activity. <h3>Objectives</h3> To determine the relation between bone density and metabolism with radiographic damage in patients with established rheumatoid arthritis (RA) under biologics. <h3>Methods</h3> Clinical features and peripheral blood samples were collected. The Portuguese version of HAQ, the disease activity score (DAS28 (4v)), the number of painful (out of 68) and swollen (out of 66) joints were obtained. We measured the following laboratory parameters: ESR and CRP, serum β-C-telopeptides of type 1 collagen cross-links (β-CTX1), osteocalcin, Dkk-1 (ELISA, Biomedica), sclerostin (ELISA TECOmedical), RANKL (ELISA, Cusabio) and OPG (ELISA, Biomedica). Bone mineral density (BMD) was assessed by Dual energy X-ray Absorptiometry (Lunar Expert ® 1320) at the lumbar spine, total hip, femoral neck, Wards triangle, hands and second proximal phalanges. Hands and feet X-ray examinations were scored according to the Sharp van der Heijde score (SHS) by a single reader. Spearman correlations were used for statistical analysis (PASW Statistics 18). <h3>Results</h3> We evaluated 104 RA patients, 88 (84,6%) women, age 52.4 ± 11.50 years, disease duration 16.7 ± 8.94 years, mean DAS28 (4v) of 4.31 ± 1.277 and a mean HAQ of 1.29 ± 0.614. In our sample, 85 (81,7%) were under anti-TNFalpha agents, 27 (26%) under bisphosphonates and 43 (41,3%) under vitamin D supplements. Total SHS and erosion score were negatively correlated with BMD at the hip (r=-0.321; p&lt;0.005 vs r=-0.326; p&lt;0.05), femoral neck (r=-0.270; p&lt;0.05 vs r=-0.282; p&lt;0.01), Wards triangle (r=-0,333; p&lt;0,005 vs r=-0,321; p&lt;0,005), lumbar spine (r=-0.261; p&lt;0.05 vs r=-0.263; p&lt;0.05), right hand (r=-0.401; p&lt;0.001 vs r=-0.417; p&lt;0.001), left hand (r=-0.449; p&lt;0.001 vs r=-0.456; p&lt;0.001), right second proximal phalange (r=-0.276; p&lt;0.05 vs r=-0.261; p&lt;0.05) and left second proximal phalange (r=-0.396; p&lt;0.001 vs r=-0.384; p=0.001). In terms of bone markers, only RANKL levels were weakly correlated with the erosion score (r=-0.218; p&lt;0.05). <h3>Conclusions</h3> In our rheumatoid arthritis population under biologics, the radiographic damage evaluated by SHS was better correlated with femoral and hands BMD than with lumbar spine BMD. RANKL seems to be the only bone marker of interest in order to define the most erosive subgroup of patients. <h3>Disclosure of Interest</h3> None Declared